Inherited Mitochondrial Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Inherited Mitochondrial Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Inherited mitochondrial disorders represent a group of genetic conditions characterized by abnormalities in mitochondrial DNA or nuclear DNA, impacting mitochondrial function. These disorders affect various organs with high energy demands, such as the brain, muscles, and heart, leading to a wide range of clinical manifestations. Examples include mitochondrial myopathy, Leigh syndrome, and MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes). Diagnosis involves genetic testing and clinical evaluation, while management focuses on symptom alleviation and supportive care, as curative therapies are currently limited.
The Inherited Mitochondrial Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Inherited Mitochondrial Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Inherited Mitochondrial Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Inherited Mitochondrial Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Inherited Mitochondrial Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Inherited Mitochondrial Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Inherited Mitochondrial Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abliva ABAutonomous University of Barcelona
Avalo Therapeutics Inc
CAMP Therapeutics Inc
Charite University Medicine Berlin
GC Biopharma Corp
Imbria Pharmaceuticals Inc
Ixchel Pharma LLC
Khondrion BV
Minovia Therapeutics Ltd
MitoRainbow Therapeutics Inc
Myto Therapeutics Inc
Neurocores Inc
Primera Therapeutics Inc
PTC Therapeutics Inc
Stealth BioTherapeutics Inc.
Taysha Gene Therapies Inc
UCB SA
Unravel Biosciences
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Inherited Mitochondrial Disorders reports